Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Interest & Investment Income (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Interest & Investment Income for 6 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 45.61% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, down 45.65% year-over-year, with the annual reading at $13.1 million for FY2025, 45.65% down from the prior year.
  • Interest & Investment Income hit $2.7 million in Q4 2025 for Lyell Immunopharma, down from $3.3 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.1 million in Q4 2023 to a low of $218000.0 in Q2 2021.
  • Historically, Interest & Investment Income has averaged $3.4 million across 5 years, with a median of $3.4 million in 2022.
  • Biggest five-year swings in Interest & Investment Income: crashed 88.41% in 2021 and later skyrocketed 1032.75% in 2023.
  • Year by year, Interest & Investment Income stood at $323000.0 in 2021, then soared by 969.04% to $3.5 million in 2022, then surged by 105.15% to $7.1 million in 2023, then plummeted by 30.55% to $4.9 million in 2024, then plummeted by 45.61% to $2.7 million in 2025.
  • Business Quant data shows Interest & Investment Income for LYEL at $2.7 million in Q4 2025, $3.3 million in Q3 2025, and $3.3 million in Q2 2025.